Trial Type
Follow-Up Treatment (Metastatic Disease)
Description for experts
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator’s Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM)
Description for laymen
JSON Data
{
"short_title": "IMCgp100-203",
"data_mode": "900",
"data_mode_number": "000002304",
"official_title": "Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigators Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM)",
"accrual_state": "running",
"therapeutic_value": "therapeutic",
"therapieansatz_value": "palliativ",
"therapieintervention_value": "not_applicable",
"therapielinie_value": "second",
"ctgov_number": "NCT05549297",
"eudract_number": null,
"general_contact_email": "oncostudien.dermatologie@ukdd.de",
"general_contact_phone": "+49 351-45819782",
"hauptpruefer_dd_name": "Prof. Dr. med. Friedegund Meier",
"description_laie_de": "Randomisierte Phase-2/3-Studie mit Tebentafusp als Monotherapie und in Kombination mit Pembrolizumab versus Investigator\u00b4s Choice bei HLA-A*02:01-positiven Teilnehmern mit vorbehandeltem fortgeschrittenem Melanom",
"description_laie_en": null,
"description_expert_de": null,
"description_expert_en": "Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator\u2019s Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM)",
"rechtsgrundlage_value": "AMG",
"phase_amg_value": "II_III",
"main_cat_id": 5,
"sub_cat_id": 35
}
